# In Vivo Therapeutics Core

> **NIH NIH P30** · INDIANA UNIVERSITY INDIANAPOLIS · 2024 · $87,400

## Abstract

ABSTRACT, In Vivo Therapeutics Core (IVTC)
The In Vivo Therapeutics Core (IVTC) is a multi-faceted Shared Resource of the Indiana University Simon
Comprehensive Cancer Center (IUSCCC) that was established to facilitate the discovery and testing of novel
pharmacological and cellular therapies. The IVTC is divided into five hubs of research expertise: breeding of
specialized mouse strains, preclinical toxicity and efficacy testing in xenograft models, patient-derived xenograft
pipelines, hematopoietic stem-cell transplant studies, and noninvasive imaging (IVIS SpectrumCT). Importantly,
the IVTC is structured in a way to provide the necessary infrastructure, oversight, and expertise required to
successfully meet the needs of IUSCCC investigators. The IVTC aligns with the IUSCCC Strategic Plan to
prioritize testing of mechanism-based therapeutics and enhance team-catalyzed research. Given the heavy
reliance of IUSCCC investigators on services provided by IVTC, there is strong rationale to support this
centralized Shared Resource that will facilitate the discovery of new therapies for cancers prominent in the
catchment area of Indiana. In FY2023, 57% of IVTC users were IUSCCC members conducting research for peer
review (scholarly papers or grant proposals); those projects accounted for >90% of the services invoiced. For
the majority of IUSCCC members, utilization of mouse models is an essential component of their ongoing
research activities focused on development of novel therapies for liquid and solid tumors. To support these
needs, the aims of the IVTC are to: 1) maintain on-site breeding colonies of mice, and establish patient-
derived xenografts essential for the exploration, testing, and refinement of novel cancer therapeutics; 2)
provide specialized core services, technology, and consultation for in vivo studies; and 3) serve as an
educational resource for IUSCCC investigators and trainees. Specifically, the IVTC manages the radiation
facility and performs irradiation services needed for in vitro and in vivo experiments, including hematopoietic
stem-cell transplantations. The IVTC coordinates all aspects of procedures and assists with experimental design,
regulatory requirements, methodology, and data interpretation for each Research Program. To increase cost-
effectiveness and improve study coordination, the IVTC assumed management of the IVIS SpectrumCT for
noninvasive tumor imaging during the current grant period. In addition, the IVTC works with IUSCCC research
teams to coordinate timely delivery of mice and samples to other core facilities in IUSCCC and the IU School of
Medicine. As a centralized facility, the IVTC will continue to provide IUSCCC investigators with advanced
resources for analytical and investigational studies essential for the preclinical validation of novel drug targets
and biomarkers of cancer so that innovative investigator-initiated trials can be successfully developed.

## Key facts

- **NIH application ID:** 10934654
- **Project number:** 2P30CA082709-25
- **Recipient organization:** INDIANA UNIVERSITY INDIANAPOLIS
- **Principal Investigator:** Karen Elizabeth Pollok
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $87,400
- **Award type:** 2
- **Project period:** 1999-09-22 → 2029-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10934654

## Citation

> US National Institutes of Health, RePORTER application 10934654, In Vivo Therapeutics Core (2P30CA082709-25). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10934654. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
